1. Market Research
  2. > Healthcare Market Trends
Interventional Cardiology Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Interventional Cardiology Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • November 2021
  • 131 pages
  • ID: 6184945
  • Format: PDF
  • Mordor Intelligence LLP


Table of Contents

Search Inside

Interventional Cardiology Devices Market was valued at USD 13.11 billion in 2020, and is projected to reach a value of USD 20.07 billion by 2026, is expected to grow annually by 7.48% CAGR 2021-2026.

The Interventional Cardiology Devices market is anticipated to have significantly impacted by the outbreak of the COVID-19 pandemic as most of the elective surgeries were deferred to contain the spread of SARS-Cov2 viral transmission. According to the research article published in Best Practice and Research: Clinical Anaesthesiology, 2020, a combined risk was associated with cardiac surgery during the COVID-19 pandemic in which both patients and well healthcare workers were at higher risk of infection. Additionally, as per the study results published in the journal of Annals of Thoracic Surgery, 2020, an estimated 53% decrease in the total cardiac surgery volume was observed in the United States in 2020 as compared to 2019, which was majorly attributed to the impact of COVID-19 pandemic. Thus, owing to the aforementioned factors, the studied market is expected to be impacted during the COVID-19 pandemic.

The major factors for the growth of the interventional cardiology devices market include the growing prevalence of coronary artery diseases (CADs), technological advancements in interventional cardiology devices, and the rising demand for minimally invasive treatment.

Heart-related diseases are the most serious health conditions and are the leading cause of death, worldwide. Coronary artery disease (CAD) is one of the most common causes of morbidity and mortality in both low-income/middle-income and developed countries. According to the British Heart Foundation Centre, in 2018, around 7.4 million people were living with heart and circulatory diseases in the United Kingdom. More than 43,000 people under the age of 75 in the United Kingdom die from heart and circulatory diseases each year. As per the American Heart Association Research Report 2018, Cardiovascular disease, listed as the underlying cause of death, accounting for nearly 836,546 deaths in the United States. This is nearly 1 out of every 3 deaths in the country and about 2,300 Americans die of cardiovascular disease each day, which is an average of 1 death every 38 seconds. Additionally, the global CVD prevalence was estimated to be almost doubled from 271 million in 1990 to 523 million in 2019, and the number of CVD deaths were found to have increased from 12.1 million in 1990, to 18.6 million in 2019 as per the research article published in Journal of the American College of Cardiology, 2020. The people suffering from cardiovascular diseases or those who are at high cardiovascular risk need early detection and management. Therefore, the increasing burden of cardiovascular diseases, including coronary artery diseases, is anticipated to boost the usage of coronary stents and drive the market studied over the forecast period.

Key Market Trends

Drug-eluting Stents Segment is Expected to Witness Significant Growth Over the Forecast Period

The Drug-eluting stents segment is predicted to dominate the studied market in the coming years. The growing adoption of advanced cardiovascular treatments and the increasing technological advancements in the field of drug-eluting stents development are the major drivers for the growth of the studied market.

Drug-eluting stents are coated with medication, which is slowly released to prevent the growth of scar tissue in the artery lining. This helps the arteries to remain smooth and open, thus, ensuring good blood flow. Drug-eluting stents are usually used for lower extremities. They provide results that are better than the self-expanding and balloon-expanding stents. A good number of patients suffering from heart problems have been successfully treated with drug-eluting stents, preventing the need for more invasive procedures, such as coronary artery bypass surgery. Drug-eluting stents help in preventing the recurrence of symptoms, such as chest pain. This also reduces the need for repetitive angioplasty procedures, which carry the risk of complications, such as heart attack and stroke. Thus, the advantages of Drug-eluting stents over other treatment options are expected to drive the studied segment growth.

Additionally, the increasing trend of product approvals is also expected to drive the segment growth. For instance, In February 2019, Biotronik received US FDA approval for its Orsiro drug-eluting stent (DES) system, which is an ultrathin, bioresorbable polymer-coated DES. Additionally, in July 2020, the Inspiron coronary sirolimus drug-eluting stent of Scitech received CE mark approval. Thus, owing to the aforementioned factors, the drug-eluting stents segments are expected to register healthy growth over the forecast period.

North America is Expected to Dominate the Interventional Cardiology Devices Market Over the Forecast Period

The presence of sophisticated healthcare infrastructure, favorable government initiatives about product development, and high patient awareness levels, coupled with relatively high healthcare expenditures in the region, are some prominent drivers for the growth of the interventional cardiology devices market in the coming years. North America has a high consumption rate of premium-priced interventional cardiology devices, and it is the region that can cater to a high rate of innovation in medical devices, thus, dominating the studied market.

According to the American Heart Association Research Report 2018, Heart disease accounts for 1 in 7 deaths in the United States. Coronary Heart Disease is the leading cause (43.8%) of deaths attributable to cardiovascular disease in the United States, followed by stroke (16.8%), heart failure (9.0%), high blood pressure (9.4%), diseases of the arteries (3.1%), and other cardiovascular diseases (17.9%). This scenario is leading to a higher demand for interventional cardiology devices for efficient treatment, which in turn is expected to drive the market in the United States. Additionally, few of the key market players in the region are involved in developing novel products and technologies to compete with the existing products while others are acquiring and partnering with the other companies trending in the market. For instance, in May 2020, Philips Image Guided Therapy Corporation received US FDA 510 (K) approval for its Reconnaissance PV .018 OTW Digital IVUS Catheter, which is indicated to be used as an adjunct to conventional angiographic procedures, to aid in diagnostic imaging of the vessel lumen and wall structures. Thus, owing to the aforementioned factors, the studied market is anticipated to witness steady growth in the North American region over the forecast period.

Competitive Landscape

The Interventional Cardiology Devices market is moderately competitive. Some of the key market players are Abbott Laboratories, B. Braun Melsungen AG, Biosensors International Ltd, Biotronik, Boston Scientific Corporation, Cardinal Health Inc., Cook Medical Inc., Medtronic plc., and Terumo Medical Corporation. The major players are involved in strategies such as investment in research and development activities, new product launches, along with forming alliances such as acquisitions, collaborations to secure the position in the global competitive market. For instance, in May 2020, Cook Medical entered into an agreement with Surmodics for the distribution of Surmodics products namely, hydrophilic percutaneous transluminal angioplasty (PTA) balloon catheters.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected]m to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Particle Size Analysis Market by Technology, Dispersion, Enduser - Global Forecasts to 2026

  • $ 4950
  • November 2021
  • 204 pages

The global particle size analysis market size is projected to reach USD 492 million by 2026 from USD 371 million in 2021, growing at a CAGR of 5.8%. The growth of the market is attributed to increasing ...

  • World
  • North America
  • Healthcare
  • Industry analysis
  • Gross Domestic Product
  • Drug Approval


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on